Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 7/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21856479 | 0.83 | CFTR (0.31) | — | |
| SCHEMBL21856401 | 0.76 | GPR119 (0.33) | SSTR4 | |
| SCHEMBL21856460 | 0.74 | MTNR1A (0.43) | FEN1OPRL1ALOX5APRORCSSTR4 | |
| SCHEMBL31071943 | 0.71 | CNR2 (0.38) | FEN1ALOX5AP | |
| SCHEMBL25907537 | 0.70 | — | — | |
| SCHEMBL21774661 | 0.68 | TRPV3 (0.36) | — | |
| SCHEMBL30149233 | 0.68 | HCAR2 (0.37) | — | |
| SCHEMBL21767320 | 0.67 | CFTR (0.39) | — | |
| SCHEMBL21767319 | 0.67 | CFTR (0.39) | — | |
| SCHEMBL22480709 | 0.67 | CYP2D6 (0.42) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528803-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3844162-B1 | INHIBITORS OF ALPHA V BETA6 INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-3844162-A1 | INHIBITORS OF av beta6 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020081154-A1 | INHIBITORS OF ανβ6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081154-A1 | INHIBITORS OF ανβ6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | FEN1 4616/4885OPRL1 1416/4885ALOX5AP 3769/4885 |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | ITGB2, ITGB6, ITGA2 | FEN1 4625/4885OPRL1 327/4885ALOX5AP 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.